Recruiting nowNot applicableInterventional
What this study is about
The objective of the proposed double-blind, parallel-arm, randomized clinical trial is to evaluate changes in body weight and composition, assess determinants of energy balance (intake and expenditure), and measure modulators of energy balance, following 8 wk of calorie restriction (-500 kcal/d) in combination with either overnight exposure to normobaric hypoxia (8 h/night, 15% FiO2, \~2640 m) or normoxia (8 h/night, 21% FiO2), using a commercially available, in-home tent system, in adults with obesity.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age22 Years to 65 Years
SexAll
Healthy volunteersAccepted
ConditionObesity
Full registry criteria
Inclusion Criteria: * Obese (BMI between 30-39.9 kg/m2) * Born at altitudes below 2,100 meters (\~7,000 feet) * Currently residing in Tallahassee, Florida or surrounding area * Completed a full FDA authorized or approved COVID-19 vaccination series at least 14 days before any in-person human research activity. * Not taking any medication(s) that interfere with oxygen delivery/transport for 4 weeks prior to and throughout the entire study (e.g., includes sedatives, sleeping aids, tranquilizers and/or any medication that depresses ventilation, diuretics, alpha and beta blockers). * Willing to refrain from smoking, vaping, chewing tobacco, and dietary supplement use throughout the entire study. * Willing to have a hypoxic tent set-up in their home and spend 8 consecutive hours per night in the tent for 8 weeks * Lives with a family member, partner/spouse, or roommate who can hear and respond in the unlikely event that the blood oxygen, air oxygen, or air carbon dioxide monitoring alarm would sound. Exclusion Criteria: * Living in areas that are more than 1,200 m (\~4,000 feet), or have traveled to areas that are more than 1,200 m for five days or more within the last 2 months * Individuals who have not completed a full FDA authorized or approved COVID-19 vaccination series at least 14 days before any in-person human research activity. * Cardiovascular abnormalities, gastrointestinal disorders, or any condition that interferes with oxygen delivery/transport (e.g., kidney disease, cardiovascular disease, etc.) * Oxygen saturation \< 95% while awake or oxygen saturation dips below 88% for a total of ≥ 10 min overnight in normoxic conditions * Evidence of apnea or other sleeping disorders * Evidence of prior high-altitude pulmonary edema (HAPE) or high-altitude cerebral edema (HACE) diagnosis * Diagnosis or family history of sickle cell anemia/trait * Hematocrit \<42% for males, \<36% for females * Hemoglobin \<13 g/dL for males, \<12 g/dL for females * Blood donation within 8 weeks of beginning the study * Present condition of alcoholism, anabolic steroids, or other substance abuse issues * Women who are pregnant, lactating, planning to become pregnant, or who have had an irregular menstrual cycle in the past 6 mo. * Weight gain or loss \> 10% of body weight during the past 6 months * Adults unable to consent
